KDR and neoplasm: Herein, we assessed the efficacy of combination therapy with FTD/TPI and DC101, an antimouse VEGFR-2 monoclonal antibody, which inhibits VEGFR-2 activity like ramucirumab and is used as a surrogate antibody for ramucirumab according to the Eli Lilly’s interview form, and we evaluated the association between this additive effect and the levels of FTD uptake into DNA and markers associated with tumor immunity.